Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Invitae Corporation    NVTA

INVITAE CORPORATION

(NVTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/18/2021 02/19/2021 02/22/2021 02/23/2021 02/24/2021 Date
47.52(c) 50.42(c) 44.81(c) 42.72(c) 42.09(c) Last
5 306 905 3 945 240 4 396 164 7 671 539 3 852 963 Volume
-0.71% +6.10% -11.13% -4.66% -1.47% Change
More quotes
Financials (USD)
Sales 2020 278 M - -
Net income 2020 -437 M - -
Net Debt 2020 36,9 M - -
P/E ratio 2020 -12,6x
Yield 2020 -
Sales 2021 460 M - -
Net income 2021 -443 M - -
Net cash position 2021 102 M - -
P/E ratio 2021 -17,6x
Yield 2021 -
Capitalization 8 024 M 8 024 M -
EV / Sales 2020 29,0x
EV / Sales 2021 17,2x
Nbr of Employees 1 900
Free-Float 99,1%
More Financials
Company
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for... 
Sector
Biotechnology & Medical Research
Calendar
02/24 | 12:00pmPresentation
More about the company
Notations Surperformance© of Invitae Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INVITAE CORPORATION
02/24INVITAE : adds Medneon's risk assessment tools to its education and clinical sup..
PR
02/23INVITAE : expands capabilities of its advanced clinical chatbot Gia, enhancing t..
PR
02/22INVITAE : to Present at The Cowen 41st Annual Healthcare Conference
PR
02/19INVITAE : Morgan Stanley Adjusts Price Target on Invitae to $45 From $41, Mainta..
MT
02/18INVITAE : Ladenburg Thalmann Upgrades Invitae to Buy From Neutral, Adjusts PT to..
MT
02/17INVITAE : 4Q Earnings Snapshot
AQ
02/17INVITAE : Q4 Net Loss Wider Than Expected as Revenue Tops Street Consensus
MT
02/17INVITAE : Fourth Quarter 2020 Financial Results Conference Call Earnings Present..
PU
02/17INVITAE CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
02/17INVITAE : Earnings Flash (NVTA) INVITAE CORPORATION Posts Q4 EPS $-0.63, vs. Str..
MT
02/17INVITAE : Earnings Flash (NVTA) INVITAE CORPORATION Reports Q4 Revenue $100.4M, ..
MT
02/17INVITAE : Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable..
PR
02/10INVITAE : to Present at the 10th Annual SVB Leerink Global Healthcare Conference
PR
02/09SoftBank to Make $900 Million Investment in Pacific Biosciences
DJ
02/03INVITAE CORP : Other Events (form 8-K)
AQ
More news
News in other languages on INVITAE CORPORATION
02/10SoftBank invertirá US$900 millones en Pacific Biosciences
01/11STRATÉGIE : les quatre meilleurs fonds US 2020
2020DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 24.06.2020 - 15.15 Uhr
2020Qiagen winkt hoher Sondergewinn aus Verkauf einer US-Beteiligung
2020Aktien Frankfurt Ausblick: Moderate Verluste erwartet
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 54,60 $
Last Close Price 42,09 $
Spread / Highest target 54,4%
Spread / Average Target 29,7%
Spread / Lowest Target 6,91%
EPS Revisions
Managers and Directors
NameTitle
Sean Emerson George Chairman, President & Chief Executive Officer
Shelly D. Guyer Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Kenneth D. Knight Chief Operating Officer
Eric I. Aguiar Independent Director
Sector and Competitors